<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND &amp; AIM: Duodeno-<z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">gastro-esophageal reflux</z:e> (DGER) as measured with <z:chebi fb="0" ids="16990">bilirubin</z:chebi> monitoring is observed in many patients with reflux disease especially in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>As acid suppression is an effective therapy of reflux disease, DGER is frequently just considered as a bystander of <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">acid reflux</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>To define the importance of DGER, reflux of duodenal contents was evaluated by <z:chebi fb="0" ids="16990">bilirubin</z:chebi> monitoring in the stomach </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: 100 patients with reflux disease were evaluated (62 m, 38 f, 50 (12) years) </plain></SENT>
<SENT sid="4" pm="."><plain>26 patients had <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, 57 had <z:hpo ids='HP_0100633'>esophagitis</z:hpo> and 17 non- erosive reflux disease (pH pos.) </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were evaluated with simultaneous 24-hour <z:chebi fb="0" ids="16990">bilirubin</z:chebi> monitoring in the esophagus and stomach </plain></SENT>
<SENT sid="6" pm="."><plain>Results were compared to 35 measurements of healthy volunteers in the esophagus and 41 measurements in the stomach </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: <z:mpath ids='MPATH_458'>Normal</z:mpath> values: DGER - Exposure time esophagus &gt; 11.8 % using an absorbance value &gt; 0.14, <z:e sem="disease" ids="C0013299" disease_type="Disease or Syndrome" abbrv="">duodenogastric reflux</z:e> (DGR) - Exposure time stomach &gt;24.8 % using an absorbance value &gt; 0.25 </plain></SENT>
<SENT sid="8" pm="."><plain>56 % of the patients had DGER, 41 % had DGR </plain></SENT>
<SENT sid="9" pm="."><plain>29 of the 41 patients with DGR had DGER (71 %), while 27 of the 56 patients with DGER had physiologic <z:e sem="disease" ids="C0013299" disease_type="Disease or Syndrome" abbrv="">duodenogastric reflux</z:e> (48 %) </plain></SENT>
<SENT sid="10" pm="."><plain>DISCUSSION: About 30 % of the patients with reflux disease show DGER combined with excessive DGR </plain></SENT>
<SENT sid="11" pm="."><plain>Therefore, DGER is not just a bystander of <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">acid reflux</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>The excessive DGR in some patients adds additional potentially dangerous substances to the <z:e sem="disease" ids="C0017168,C0559234" disease_type="Disease or Syndrome;Finding" abbrv="">esophageal reflux</z:e> </plain></SENT>
</text></document>